Q1: 2026-05-12 Earnings Abstract
EPS of -$0.83 misses by $0.05
| Income of $18.27M (29.47% Y/Y) misses by $7.65M
Kura Oncology, Inc. (KURA) Financial institution of America World Healthcare Convention 2026 Might 13, 2026 6:00 PM EDT
Firm Members
Troy Wilson – Chairman, CEO & President
Brian Powl – Chief Industrial Officer
Convention Name Members
Jason Zemansky – BofA Securities, Analysis Division
Presentation
Jason Zemansky
BofA Securities, Analysis Division
[Audio Gap] BofA Well being Care Convention in very [ thirsty ] Las Vegas. My title is Jason Zemansky. I am one of many SMID cap analyst right here at BofA, and I am more than happy to have with us on stage, Kura. Troy Wilson, CEO; and Brian Powl. Thanks a lot for becoming a member of us.
Troy Wilson
Chairman, CEO & President
Thanks, Jason.
Brian Powl
Chief Industrial Officer
Thanks.
Jason Zemansky
BofA Securities, Analysis Division
Perhaps to start out it broadly for many who aren’t aware of the Kura story, may you please present a short overview of zifto and darli?
Query-and-Reply Session
Troy Wilson
Chairman, CEO & President
Positive. Sure. So on the 1 aspect, you’ve got ziftomenib, or business title KOMZIFTI. We’ve approval within the relapsed/refractory NPM1-mutant setting. Our objective is to be the market chief to drive sustainable quarter-over-quarter development there. We’ve, I feel, the most important most complete Section III growth program in each the intensive and nonintensive frontline setting. We’ll be giving a knowledge replace on that right here in a number of weeks. After which we now have intensive research, taking a look at totally different mixtures to actually have the ability to advance the usual of care and get ziftomenib all through the therapy continuum in AML.
We’re additionally finding out ziftomenib in gastrointestinal stromal tumors or GIST. We’re making good progress in dose escalation, most likely not taking a look at a day to replace till subsequent yr, however positively some potential there in addition to investigating different stable tumors.
Shifting to the darlifarnib aspect, darlifarnib is actually making an attempt to
